JP2016510797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016510797A5 JP2016510797A5 JP2015562215A JP2015562215A JP2016510797A5 JP 2016510797 A5 JP2016510797 A5 JP 2016510797A5 JP 2015562215 A JP2015562215 A JP 2015562215A JP 2015562215 A JP2015562215 A JP 2015562215A JP 2016510797 A5 JP2016510797 A5 JP 2016510797A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- het
- independently
- cycloalkyl
- halo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000000217 alkyl group Chemical group 0.000 claims 333
- 125000001475 halogen functional group Chemical group 0.000 claims 69
- 125000001424 substituent group Chemical group 0.000 claims 48
- -1 R 2 is -H Chemical group 0.000 claims 17
- 229910052757 nitrogen Inorganic materials 0.000 claims 17
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000000753 cycloalkyl group Chemical group 0.000 claims 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 12
- 239000003814 drug Substances 0.000 claims 9
- 125000005842 heteroatom Chemical group 0.000 claims 9
- 239000002207 metabolite Substances 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 239000000651 prodrug Substances 0.000 claims 9
- 229940002612 prodrug Drugs 0.000 claims 9
- 230000000069 prophylactic effect Effects 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 229910052717 sulfur Inorganic materials 0.000 claims 9
- 229940124597 therapeutic agent Drugs 0.000 claims 9
- 239000000032 diagnostic agent Substances 0.000 claims 8
- 229940039227 diagnostic agent Drugs 0.000 claims 8
- 108091000080 Phosphotransferase Proteins 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 7
- 102000020233 phosphotransferase Human genes 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 6
- 208000035475 disorder Diseases 0.000 claims 6
- 125000000623 heterocyclic group Chemical group 0.000 claims 6
- 150000001204 N-oxides Chemical class 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- MJQSRSOTRPMVKB-UHFFFAOYSA-N 5h-imidazo[4,5-c]pyridazine Chemical group C1=NNC2=NC=NC2=C1 MJQSRSOTRPMVKB-UHFFFAOYSA-N 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical group C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 claims 1
- 208000016097 disease of metabolism Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 208000030159 metabolic disease Diseases 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2013055389 | 2013-03-15 | ||
| EPPCT/EP2013/055389 | 2013-03-15 | ||
| PCT/EP2014/055168 WO2014140313A1 (en) | 2013-03-15 | 2014-03-14 | Macrocyclic salt-inducible kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016510797A JP2016510797A (ja) | 2016-04-11 |
| JP2016510797A5 true JP2016510797A5 (enExample) | 2017-03-30 |
Family
ID=50588637
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015562215A Ceased JP2016510797A (ja) | 2013-03-15 | 2014-03-14 | 大環状塩誘導性キナーゼ阻害剤 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9586975B2 (enExample) |
| JP (1) | JP2016510797A (enExample) |
| KR (1) | KR20150133767A (enExample) |
| CN (1) | CN105209040A (enExample) |
| AU (1) | AU2014230125A1 (enExample) |
| BR (1) | BR112015022650A8 (enExample) |
| CA (1) | CA2906262A1 (enExample) |
| EA (1) | EA201591794A1 (enExample) |
| HK (1) | HK1219057A1 (enExample) |
| IL (1) | IL241325A0 (enExample) |
| MX (1) | MX2015012528A (enExample) |
| SG (1) | SG11201507493SA (enExample) |
| WO (1) | WO2014140313A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016510796A (ja) * | 2013-03-15 | 2016-04-11 | オンコデザイン エス．ア． | 大環状ｒｉｐ２キナーゼ阻害剤 |
| CA2954186A1 (en) | 2014-07-21 | 2016-01-28 | Dana-Farber Cancer Institute, Inc. | Imidazolyl kinase inhibitors and uses thereof |
| EP4047001A3 (en) | 2016-07-05 | 2022-11-30 | The Broad Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| WO2018053373A1 (en) * | 2016-09-16 | 2018-03-22 | The General Hospital Corporation | Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis |
| JP7296318B2 (ja) | 2017-02-28 | 2023-06-22 | ザ ジェネラル ホスピタル コーポレイション | Ｓｉｋインヒビターとしてのピリミドピリミジノンの使用 |
| DK3391907T3 (da) | 2017-04-20 | 2020-03-09 | Iomx Therapeutics Ag | Intracellulær kinase sik3, der er associeret med resistens over for antitumorimmunresponser, og anvendelser deraf |
| CN109956957B (zh) * | 2017-12-22 | 2021-11-09 | 广州白云山医药集团股份有限公司白云山制药总厂 | 一种咪唑并[1,2-b]哒嗪大环类激酶抑制剂 |
| JPWO2020027200A1 (ja) | 2018-08-01 | 2021-08-19 | 小野薬品工業株式会社 | 軟骨関連疾患治療剤 |
| US11690897B2 (en) | 2019-02-04 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Salt inducible kinase inhibitors for enhancing fertility |
| CN115698020B (zh) * | 2020-01-31 | 2025-02-25 | 昂科迪塞恩精密医药公司(Opm) | 大环rip2-激酶抑制剂 |
| AU2023339247A1 (en) * | 2022-09-07 | 2025-03-27 | Suzhou Langrui Biopharmaceutical Co., Ltd. | Macrocyclic imidazo[1,2-b]pyridazine derivative, preparation method therefor, and use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IS2334B (is) | 1992-09-08 | 2008-02-15 | Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) | Aspartyl próteasi hemjari af nýjum flokki súlfonamíða |
| BR9407686A (pt) | 1993-10-01 | 1997-02-04 | Astra Ab | Processo e aparelho para o tratamento de um medicamento em pó finamente dividido uso do aparelho e aglomerados |
| US6043358A (en) | 1995-11-01 | 2000-03-28 | Merck & Co., Inc. | Hexahydro-5-imino-1,4-heteroazepine derivatives as inhibitors of nitric oxide synthases |
| GB9718913D0 (en) | 1997-09-05 | 1997-11-12 | Glaxo Group Ltd | Substituted oxindole derivatives |
| US6369087B1 (en) | 1999-08-26 | 2002-04-09 | Robert R. Whittle | Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same |
| US7517882B2 (en) * | 2006-09-18 | 2009-04-14 | Polaris Group | Protein kinase inhibitors |
| NZ576234A (en) * | 2006-11-06 | 2011-06-30 | Supergen Inc | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| WO2008060248A1 (en) * | 2006-11-15 | 2008-05-22 | S*Bio Pte Ltd. | Indole sustituted pyrimidines and use thereof in the treatment of cancer |
| CN102056927B (zh) * | 2008-05-13 | 2014-06-25 | Irm责任有限公司 | 作为激酶抑制剂的稠合含氮杂环及其组合物 |
| EP2760453B1 (en) * | 2011-09-30 | 2016-05-25 | Ipsen Pharma S.A.S. | Macrocyclic lrrk2 kinase inhibitors |
| HUE027318T2 (en) * | 2011-09-30 | 2016-10-28 | Oncodesign Sa | Macrocyclic FLT3 kinase inhibitors |
-
2014
- 2014-03-14 EA EA201591794A patent/EA201591794A1/ru unknown
- 2014-03-14 AU AU2014230125A patent/AU2014230125A1/en not_active Abandoned
- 2014-03-14 US US14/776,798 patent/US9586975B2/en not_active Expired - Fee Related
- 2014-03-14 JP JP2015562215A patent/JP2016510797A/ja not_active Ceased
- 2014-03-14 BR BR112015022650A patent/BR112015022650A8/pt not_active IP Right Cessation
- 2014-03-14 WO PCT/EP2014/055168 patent/WO2014140313A1/en not_active Ceased
- 2014-03-14 MX MX2015012528A patent/MX2015012528A/es unknown
- 2014-03-14 HK HK16107168.3A patent/HK1219057A1/zh unknown
- 2014-03-14 SG SG11201507493SA patent/SG11201507493SA/en unknown
- 2014-03-14 CN CN201480023832.3A patent/CN105209040A/zh active Pending
- 2014-03-14 CA CA2906262A patent/CA2906262A1/en not_active Abandoned
- 2014-03-14 KR KR1020157029486A patent/KR20150133767A/ko not_active Withdrawn
-
2015
- 2015-09-08 IL IL241325A patent/IL241325A0/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016510797A5 (enExample) | ||
| JP2016510796A5 (enExample) | ||
| JP2017529365A5 (enExample) | ||
| JP2019536785A5 (enExample) | ||
| RU2014117515A (ru) | Макроциклические ингибиторы киназы lrrk2 | |
| RU2012148246A (ru) | 5, 7- замещенные-имидазо[1, 2-с]пиримидины как ингибиторы jak-киназ | |
| RU2012119488A (ru) | Конденсированные азиновые производные для лечения заболеваний, связанных с ацетилхолиновым рецептором | |
| JP2019512505A5 (enExample) | ||
| CN108137590B (zh) | 作为mdm2-p53抑制剂的新的螺(3h-吲哚-3,2′-吡咯烷)-2(1h)-酮化合物及其衍生物 | |
| JP2016531858A5 (enExample) | ||
| JP2017511815A5 (enExample) | ||
| JP2016523270A5 (enExample) | ||
| JP2018514518A5 (enExample) | ||
| JPWO2020122093A5 (enExample) | ||
| JP2018515525A5 (enExample) | ||
| WO2016097869A4 (en) | Fused ring heteroaryl compounds and their use as trk inhibitors | |
| JP2019522055A5 (enExample) | ||
| JP2016530262A5 (enExample) | ||
| JP2013523884A5 (enExample) | ||
| JP2012511588A5 (enExample) | ||
| JP2016525136A5 (enExample) | ||
| JPWO2019213526A5 (enExample) | ||
| JP2017512833A5 (enExample) | ||
| JP2017505762A5 (enExample) | ||
| JP2011522866A5 (enExample) |